Meeting
2018 ASCO Annual Meeting
Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).
Authors
Gurpreet Kapoor
Scientific Operations, LabConnect LLC, Seattle, WA
Gurpreet Kapoor , Weimin Li , Dong Shen , Roland Elmar Knoblauch , Michael Gormley , George C. Wang , Deborah S. Ricci , Michael P. Smith , Clifford Motley , Sigrid Malbrain , Robert G. Maki , Margaret vonMehren , Shreyaskumar Patel , George D. Demetri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11513)
DOI
10.1200/JCO.2018.36.15_suppl.11513
Abstract #
11513
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
First Author: Mrinal M. Gounder
First Author: Albert Grinshpun
Poster
2022 ASCO Annual Meeting
Genomic analysis and prediction of therapeutic vulnerabilities of small cell lung cancer from rovalpituzumab tesirine phase III trial (MERU).
First Author: Weilong Zhao